Related Experiment Videos
[Study on the prostatic tissue levels of cefmenoxime (CMX)]
Hinyokika Kiyo. Acta Urologica Japonica
|February 1, 1985
Summary
Cefmenoxime (CMX) effectively penetrates prostatic tissue, reaching concentrations above the minimum inhibitory level for common pathogens. This suggests CMX is a suitable antibiotic for treating prostate infections.
Area of Science:
- Pharmacology
- Infectious Diseases
Context:
- Assessing antibiotic efficacy in genitourinary infections.
- Evaluating drug penetration into specific tissues is crucial for treatment success.
Purpose:
- To determine Cefmenoxime (CMX) concentrations in serum and prostatic tissue.
- To analyze the pharmacokinetic profile of CMX in patients undergoing prostatectomy.
Summary:
- Cefmenoxime (CMX) administered intravenously achieved peak serum levels of 124 µg/ml with a 1.07-hour half-life.
- Prostatic tissue CMX levels peaked at 35.7 µg/g, with a tissue-to-serum AUC ratio of 33% and a 1.07-hour half-life.
- CMX concentrations in prostatic tissue exceeded MIC80 for E. coli and Klebsiella sp., indicating potential therapeutic value.
Impact:
- Cefmenoxime (CMX) demonstrates favorable pharmacokinetic properties for treating prostate infections.
- Results support the use of CMX for chronic prostatitis and post-operative prostate infections.
- This study provides evidence for CMX as a preferred antibiotic option in urological settings.